drugset / Trial / NCT00126464

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

NCT00126464

Unknown 100 enrolled Cedars-Sinai Medical Center
RandomizedTreatment

Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant or tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving fulvestrant or tamoxifen before surgery may be an effective treatment for breast cancer. PURPOSE: This randomized clinical trial is studying how well giving fulvestrant or tamoxifen works in treating postmenopausal women who are undergoing surgery for ductal carcinoma in situ of the breast.

Timeline

Start
2004-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fulvestrant Small molecule Intramuscular
Subject Tamoxifen Small molecule Oral

Indications